Indefinite Delivery Contract SPE2DB25D9307

The Defense Logistics Agency (DLA) has awarded DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois, a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 through November 2026. This IDC, under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military healthcare facilities nationwide. The contract covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories, including injections, tablets, creams, auto-injectors, and specialty medications.

As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated its capability to provide a diverse array of pharmaceutical products to the DLA, including specialized medications such as Xolair, Trikafta, Keytruda, Botox, and Nucala. The IDC allows DLA to issue firm fixed-price delivery orders for these and other prescription drugs and medical supplies to support the healthcare requirements of the Department of Defense. This contract, which is not associated with any specific set-aside designations, leverages DMS Pharmaceutical Group's status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.